What is GenoME Diagnostics?
Headquartered in Belfast, Northern Ireland, GenoME Diagnostics is a specialized biotechnology firm originating as a spinout from Queen's University. The company is dedicated to the development of novel blood-based diagnostic assays designed to facilitate the earlier and more precise detection of ovarian cancer. By leveraging advanced molecular research, GenoME Diagnostics aims to address critical gaps in current screening protocols, positioning itself as a pivotal player in the precision medicine sector. Its market position is bolstered by strong institutional ties and a focus on high-impact clinical outcomes.
How much funding has GenoME Diagnostics raised?
GenoME Diagnostics has raised a total of $2M across 2 funding rounds:
Angel/Seed
$424K
Other Financing Round
$1.6M
Angel/Seed (2021): $424K with participation from Co-Fund NI, Deepbridge Capital, and QUBIS
Other Financing Round (2023): $1.6M led by Deepbridge Capital and QUBIS
Key Investors in GenoME Diagnostics
Deepbridge Capital
Deepbridge Syndicate is a private investor network that caters to experienced investors and family offices, allowing them to create personalized portfolios of innovative Life Sciences and Technology companies.
QUBIS
QUBIS Ltd collaborates with academic entrepreneurs to transform high-quality research from Queens University, Belfast into commercially viable spinoff companies.
Co-Fund NI
Co-Fund NI is an investment fund that provides equity financing to high-growth potential businesses in Northern Ireland, often co-investing alongside private sector partners.
What's next for GenoME Diagnostics?
With the recent capital infusion, GenoME Diagnostics is well-positioned to advance its diagnostic pipeline through rigorous clinical validation and regulatory milestones. The company's strategic roadmap likely involves scaling its laboratory infrastructure and strengthening its intellectual property portfolio to support broader market adoption. By focusing on the intersection of academic innovation and commercial scalability, the firm is poised to enhance its diagnostic accuracy, ultimately aiming to improve patient survival rates through early intervention strategies in the oncology market.
See full GenoME Diagnostics company page
